Page 3 - Shimadzu Journal vol.9 Issue1

Note from the Director

Firstly, we interviewed Professor Uwe Karst of the accordance with the anticipated increase in the el-
University of Münster about his participation in the derly population in every country and region of the
development of a multimodal imaging system. Next, globe. In order to extend this healthy lifespan, I be-
we talked with Dr. Paul Eason at the University of lieve it is very important to detect cancer, cognitive
North Florida (UNF) about MedNexus, a facility es- illnesses, and other diseases at very early stages and
tablished by UNF and associated with comprehen- to take appropriate treatments and countermea-
sive medical treatment and health care, and also sures. In order to contribute to these fields, Shimadzu
about the relationship with Shimadzu. will take proactive measures in the area of coopera-
In addition to these interviews, this tive research, deepening our relationships with re-
issue contains applications related to searchers involved in cutting-edge, revolutionary
the screening of anticancer agents research and development in these clinical research
using probe electrospray ionization fields, based on Shimadzu’s advanced analytical and
(PESI) and analysis of COVID-19 measuring technologies.
therapeutic drugs using HPLC The corporate philosophy of Shimadzu is “Con-
and LC-MS/MS. Finally, we tributing to Society through Science and Techno-
introduce the latest initia- logy.” To realize this corporate philosophy, we will
tives at Shimadzu in the continue to maintain a proactive exchange of infor-
clinical research field. mation and, at the same time, provide useful infor-
I believe the impor- mation to you. We hope that this journal will be a
tance of a healthy lifes- great help for all of you. Your generous feedback is
pan is increasing in always appreciated.

Yours Sincerely,

Shimadzu Journal vol.9 Issue1 2